Volume 3.40 | Oct 13

Mammary Cell News 3.40, October 13, 2011
     In this issue: Publications | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  Mammary Cell News on Twitter

Distinct Stem Cells Contribute to Mammary Gland Development and Maintenance
To define the cellular hierarchy of the mammary gland during physiological conditions, scientists performed genetic lineage-tracing experiments and clonal analysis of the mouse mammary gland during development, adulthood and pregnancy. [Nature] Abstract | Press Release


PUBLICATIONS (Ranked by Impact Factor of the Journal)


Genomic Analysis of Circulating Cell Free DNA Infers Breast Cancer Dormancy
Scientists hypothesized that genomic analysis of circulating free DNA isolated from plasma may form the basis for a means of detecting and monitoring breast cancer. [Genome Res] Abstract

Mutation of a Single Allele of the Cancer Susceptibility Gene BRCA1 Leads to Genomic Instability in Human Breast Epithelial Cells
Here, researchers show that heterozygous BRCA1 inactivation results in genomic instability in nontumorigenic human breast epithelial cells in vitro and in vivo. [Proc Natl Acad Sci USA] Abstract

Mitochondrial Targeting Liposomes Incorporating Daunorubicin and Quinacrine for Treatment of Relapsed Breast Cancer Arising from Cancer Stem Cells
The objectives of this study were to construct a kind of mitochondrial targeting daunorubicin plus quinacrine liposomes for treating and for preventing the recurrence of breast cancer arising from the cancer stem cells. [Biomaterials] Abstract

Cytoplasmic Estrogen Receptor in Breast Cancer
Investigators sought to determine the presence and implications of non-nuclear estrogen receptors in clinical specimens. [Clin Cancer Res] Abstract

Chronic Oral Exposure to Bisphenol A Results in a Non-Monotonic Dose Response in Mammary Carcinogenesis and Metastasis in MMTV-ErbB2 Mice
This study investigated the role of chronic, oral exposure to bisphenol A during adulthood on mammary carcinogenesis by using a transgenic mouse model which spontaneously develops tumors through over-expression of wildtype erbB2 (MMTV-erbB2). [Environ Health Perspect] Abstract | Press Release

αB-Crystallin, an Effecter of Unfolded Protein Response, Confers Anti-VEGF Resistance to Breast Cancer via Maintenance of Intracrine VEGF in Endothelial Cells
Findings underscore the importance of defining a role for intracrine VEGF signaling in sustaining aberrant tumor angiogenesis and strongly implicate unfolded protein response/αB-crystallin as dichotomous parts of a crucial regulation pathway for maintaining intracrine VEGF signaling. [Mol Cancer Res] Abstract


High False-Negative Rate of HER2 Quantitative Reverse Transcription Polymerase Chain Reaction of the Oncotype DX Test: An Independent Quality Assurance Study
This quality assurance study was undertaken to define the concordance rate between immunohistochemistry/fluorescent in situ hybridization and Genomic Health reverse transcription polymerase chain reaction HER2 assay. [J Clin Oncol] Abstract

RIBBON-2: A Randomized, Double-Blind, Placebo-Controlled, Phase III Trial Evaluating the Efficacy and Safety of Bevacizumab in Combination with Chemotherapy for Second-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer
This phase III study compared the efficacy and safety of bevacizumab combined with standard chemotherapy regimens versus chemotherapy alone as second-line treatment of patients with human epidermal growth factor receptor 2–negative metastatic breast cancer. [J Clin Oncol] Abstract

Prognostic Value of a Combined Estrogen Receptor, Progesterone Receptor, Ki-67, and Human Epidermal Growth Factor Receptor 2 Immunohistochemical Score and Comparison with the Genomic Health Recurrence Score in Early Breast Cancer
This study suggests that the amount of prognostic information contained in four widely performed immunohistochemical assays is similar to that in the Genomic Health recurrence score. [J Clin Oncol] Abstract



Advaxis Granted Pre-IND Meeting with FDA for ADXS-HER2, an Immunotherapy for HER2 Expressing Cancers
Advaxis, Inc., has been granted a pre-Investigational New Drug (IND) meeting with the U.S. Food and Drug Administration (FDA) on November 22nd, 2011 to discuss the initial clinical development plan for ADXS-HER2. [Advaxis, Inc.] Press Release

Genesis Biopharma Signs Worldwide License Agreement with the NIH for Adoptive Cell Therapy to Treat a Variety of Cancers
Genesis Biopharma, Inc. announced it has entered into a Patent License Agreement with the National Institutes of Health (NIH). [Genesis Biopharma, Inc.] Press Release

Fred Hutchinson Cancer Research Center Breaks Ground for First Collaborative, Comprehensive Cancer Center in Sub-Saharan Africa
A pioneering international collaboration forged by Fred Hutchinson Cancer Research Center together with the Uganda Cancer Institute has broken ground for the future construction of a state-of-the-art cancer training and outpatient treatment facility in Kampala. [Fred Hutchinson Cancer Research Center] Press Release

Maryland Stem Cell Research Commission Issues Requests for Applications
Per the Maryland Stem Cell Commission (Commission) meeting on Sept.15, 2010, the Commission has issued three official Requests for Applications for funding through the Maryland Stem Cell Research Fund under the Maryland Stem Cell Research Act. [Maryland Stem Cell Research Fund] Press Release


Veto Angers Supporters of Breast Density Notification Bill
Governor Jerry Brown’s veto of a bill that would have required California physicians to tell patients when screening mammography uncovers dense breast tissue has angered supporters looking to take their campaign nationwide. [Governor Jerry Brown, United States] Press Release

Scottish Medicines Consortium Does Not Recommend Eribulin (Halaven®) for Use in NHS Scotland for Breast Cancer
The Scottish Medicines Consortium does not recommend eribulin (Halaven®) for use in National Health Service (NHS) Scotland for the treatment of patients with locally advanced or metastatic breast cancer who have progressed after at least two chemotherapeutic regimens for advanced disease. [Scottish Medicines Consortium, Scotland] Press Release

National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)


NEW Continuing Medical Education: Chemotherapy for Women with Heavily Pre-Treated Metastatic Breast Cancer: A Review of the Evidence Base
October 27, 2011

NEW Stem Cells in Drug Discovery and Development
November 2-3, 2011
San Diego, United States 

our events page to see a complete list of events in the mammary cell community.


Lab Technologist – Tissue Culture (STEMCELL Technologies)

Research and Development Technologist, hPSC Media (STEMCELL Technologies)

Scientist (iPSC) (STEMCELL Technologies)

Contract Assay Service Technologist (STEMCELL Technologies)

Lab Technologist – Pluripotent Stem Cells (STEMCELL Technologies)

Quality Control Technologist – Cell Separation (STEMCELL Technologies)

Scientist – Pluripotent Stem Cells (STEMCELL Technologies)

Postdoctoral Fellow in Breast Cancer (Indiana University School of Medicine)

Research Fellow in Breast Cancer Research (Monash University)

Postdoctoral Fellow in Breast Cancer (Indiana University School of Medicine)

Recruit Top Talent

Reach more than 11,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Jobs are categorized regionally: United States, Canada, Europe, Asia Pacific

Visit here to post your career opportunities.

Have we missed an important article or publication in Mammary Cell News? Click here to submit!

Comments or Suggestions? Email [email protected] with your feedback.

Learn more about Mammary Cell News: Archives | Events | Contact Us